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ABSTRACT
Resistance to androgen receptor (AR) targeting ther-
apeutics in prostate cancer (PC) is a significant clin-
ical problem. Mechanisms by which this is accom-
plished include AR amplification and expression of
AR splice variants, demonstrating that AR remains a
key therapeutic target in advanced disease. For the
first time we show that IKBKE drives AR signalling
in advanced PC. Significant inhibition of AR regu-
lated gene expression was observed upon siRNA-
mediated IKBKE depletion or pharmacological inhi-
bition due to inhibited AR gene expression in multiple
cell line models including a LNCaP derivative cell line
resistant to the anti-androgen, enzalutamide (LNCaP-
EnzR). Phenotypically, this resulted in significant in-
hibition of proliferation, migration and colony form-
ing ability suggesting that targeting IKBKE could
circumvent resistance to AR targeting therapies. In-
deed, pharmacological inhibition in the CWR22Rv1
xenograft mouse model reduced tumour size and
enhanced survival. Critically, this was validated in
patient-derived explants where enzymatic inactiva-
tion of IKBKE reduced cell proliferation and AR ex-
pression. Mechanistically, we provide evidence that
IKBKE regulates AR levels via Hippo pathway inhi-
bition to reduce c-MYC levels at cis-regulatory ele-
ments within the AR gene. Thus, IKBKE is a therapeu-
tic target in advanced PC suggesting repurposing of
clinically tested IKBKE inhibitors could be beneficial
to castrate resistant PC patients.
INTRODUCTION
The androgen receptor (AR) is a key molecule in the de-
velopment and progression of prostate cancer (PC) and
as such is a critical therapeutic target. Current androgen-
deprivation therapy (ADT) is initially effective at reducing
AR signalling and PC progression, but most patients in-
evitably become resistant to these treatments via multiple
mechanisms including AR gene amplification and through
AR splice variants (1). Therefore, the AR remains a key
therapeutic target in ADT-resistant disease and the devel-
opment of new AR-targeted therapies, although challeng-
ing, remains a major unmet clinical need for PC treatment.
AR activity is regulated by numerous post-translational
modifications (PTM) which suggests that targeting AR
modifying enzymes which enhance AR activity may pro-
vide therapeutic benefit when direct AR targeting thera-
pies have failed; particularly as a number of these coregu-
latory proteins are themselves often dysregulated in PC (2).
The best characterized PTM of the AR is phosphorylation
(AR-P), where phosphorylation at specific sites determines
its biological consequences. For example, phosphorylation
at Ser308 by Cyclin D3/CDK11p58 inhibits the transcrip-
tional activity of theAR (3) whilst phosphorylation at Ser81
is linked to transcriptional activation (4). In addition, AR-
P can occur under steroid depleted conditions for exam-
ple, AKT enhances receptor phosphorylation at Ser213 to
promote nuclear translocation in response to IGF1 in the
absence of androgens (5), and EGF can activate the AR
by Ser515 phosphorylation (6). Indeed, many reports have
linked the phosphorylation status of the AR with more ag-
gressive disease (7–9). Additionally, manyAR co-regulators
are similarly regulated via phosphorylation (10,11).
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IKBKE (IKKE, IKKi) is a non-canonical I-kappa-B ki-
nase which can be activated by numerous stimuli includ-
ing TNF and IL1. It plays a role in numerous signalling
pathways, for example it has been shown to phosphorylate
CYLD, which in turn activates theNF-B pathway via deu-
biquitination of several NF-B regulator proteins (12). IK-
BKE can also inactivate the Hippo pathway, which is re-
sponsible for regulating organ size, by phosphorylation of
LATS1/2 to result in its degradation (13). Furthermore, IK-
BKE can regulate the stability and nuclear localization of c-
MYC in pancreatic ductal carcinoma cell lines (14). In sev-
eral cancers, IKBKE has been demonstrated to be ampli-
fied and overexpressed (12) moreover, it has been found to
be oncogenic in breast and ovarian cancer (15,16). Interest-
ingly, in PC, IKBKE exhibits elevated protein expression in
cancers compared to normal cells (17).
In this study, we identified IKBKE as a regulator of AR
transcriptional activity which engages the Hippo pathway
to modulate AR de novo synthesis in models of PC. Tar-
geting IKBKE with small molecule inhibitors in both PC
cell line xenografts and patient ex vivo explant models re-
sulted in reduced tumour volume, inhibition of proliferation
and reduced AR expression. Collectively, our data suggest
that IKBKE is a viable therapeutic target for the treatment
of PC. Interestingly, pharmacological inhibitors of IKBKE
are used in treatment of asthma, allergic rhinitis and apht-
hous ulcers (18,19) and a potential role for these inhibitors
has also been identified in obesity related metabolic disor-
ders (20), lung cancer (21) and glioblastoma (13). We pro-
pose that IKBKE inhibitors, such as Amlexanox which has
been used in clinical trials for Type 2 diabetes (22), may be
repurposed to provide therapeutic advantage for advanced
PC patients.
MATERIALS AND METHODS
Antibodies and constructs
AR (C-19, sc-815, Santa Cruz Biotechnology and clone
G122-434, BD), PSA (A0562, Dako), IKBKE (D20G4,
Cell Signalling), -tubulin (clone DM1A, T9026, Sigma),
LATS2 (kpm C-2, sc-515579 Santa Cruz Biotechnology),
YAP (G-6, sc-376830 Santa Cruz Biotechnology), c-MYC
(ab56, Abcam and N262, sc-764, Santa Cruz Biotechnol-
ogy), TMPRSS2 (H-4, sc-515727, Santa Cruz Biotechnol-
ogy), PARP1/2 (clone H250, sc-7150, Santa Cruz Biotech-
nology), FKBP5 (D-4, sc-271547, Santa Cruz Biotechnol-
ogy), GFP (ab290, AbCam) Ki67 (clone MM1, Novocas-
tra, Leica Biotechnology).
Compounds
All compounds were purchased in powder form and re-
suspended in DMSO to a concentration of 10 mM unless
otherwise stated. CAY10576 (Santa Cruz Biotechnology),
MRT67307 (Stratech Scientific), BX795 (Cambridge Bio-
Science), CYT387 (AdooqBiosciences andCambridge Bio-
Science), Ruxolitinib (Cambridge BioScience) and R1881
(Sigma) were stored at −80◦C for no more than 6 months.
Enzalutamide (Selleckchem) was prepared at a concentra-
tion of 30 mM and stored at −80◦C for no more than 6
months. MG-132 (Sigma) was purchased as a 10 mM stock
in DMSO and stored at −80◦C.
Cell culture
VCaP, CWR22Rv1 (23), PC3 and LNCaP cells were
obtained from the American Type Culture Collection
(Manasses, VA, USA) and LNCaP-7B7 cells (24) were
a gift from Professor Jan Trapman (Erasmus Medical
Centre, Rotterdam), LAPC4 were a gift from Helmut
Klocker (Innsbruck). Cells were maintained in RPMI-
1640 media (Sigma) containing 10% (v/v) Foetal Calf
Serum (FCS) (Gibco) and 2 mM L-glutamine (Sigma)
at 37◦C in 5% CO2 atmosphere. LNCaP-AI (25) were
maintained in RPMI-1640 media containing 10% dex-
tran coated charcoal stripped serum FCS (Biowest) and
2 mM L-glutamine. LNCaP-AI AREIII-LUC cells were
generated in house as described in Supplementary Mate-
rials and Methods and maintained under the same con-
ditions as LNCaP-AI cells. LNCaP-AR-GFP, LNCaP-EV
and LNCaP-YapS127A cells were generated in house as de-
scribed in SupplementaryMaterials andMethods. LNCaP-
EnzR cells were generated in house by serially maintain-
ing LNCaP cells in RPMI-1640 media containing 10% FCS
and 2 mM L-glutamine, supplemented with 10 MEnzalu-
tamide. LAPC4 cells were maintained in RPMI-1640media
containing 10% FCS and 2 mM L-glutamine (Sigma), sup-
plemented with 1 nM R1881. VCaP cells were maintained
in High Glucose DMEM-6171 media (Sigma) containing
10% FCS and 2 mM L-glutamine.
For androgen stimulation assays, cells were grown in
RPMI-1640media (Gibco) supplementedwith 10%dextran
coated charcoal stripped serumFCS and 2mML-glutamine
for 72 h, prior to the addition of 1 nM R1881 for indicated
lengths of time.
Cell line authentication was performed by short tandem
repeat profiling (NewGene, Newcastle upon Tyne, UK) and
mycoplasma testing was performed routinely using My-
coAlert kit (Lonza, UK).
siRNA
Cell lines were reverse transfected with individual siRNAs
(25 nM) using Lipofectamine RNAiMAX (Invitrogen) ac-
cording to manufacturer’s instructions (for siRNA target
sequences see Supplementary Table S1). To assess siRNA
knockdown either RNA or protein was collected and sub-
jected to qPCR or western blotting, respectively, as de-
scribed below.
Nuclear-cytoplasmic fractionation
LNCaP cells were cultured as previously described and
treated with DMSO or IKBKE inhibitors CAY10576 (5
M) or CYT387 (5 M) for 16 h. For knockdown exper-
iments, cells were reverse transfected as detailed above and
cells collected after 72 h knockdown. Nuclear-cytoplasmic
fractionation was performed using the NE-PER Nuclear
and Cytoplasmic Extraction Kit (Thermo Scientific) ac-
cording to the manufacturer’s protocol and analysed by
western blotting.
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Colony formation assay
LNCaP and LNCaP-Enz cells were reverse transfected with
25 nM N/S or IKBKE siRNA and incubated for 72 h.
Cells were then reseeded and incubated for 21 days to allow
colony formation. Cells were then fixed and stained with
crystal violet. Colonies were counted and the surviving frac-
tion calculated.
Migration assay
LNCaP cells were either reverse transfected with 25 nM
N/S or IKBKE siRNA and incubated for 72 h or pre-
treated with CAY10576 for 24 h prior to seeding intomigra-
tion chambers in basal media and inserted into wells con-
taining serum supplemented media as a chemoattractant.
Cells were incubated for 16 h, then inner chambers scrubbed
to remove cells which did not migrate through the pores of
the membrane. Cells which had migrated to the other side
of the membrane were then fixed in ice cold methanol and
stained with haematoxylin. Cells were then imaged using
Aperio CS2Digital Pathology scanner (Leica) and counted.
Western blotting
Western analysis was performed as previously described
(26).
Quantitative polymerase chain reaction
RNA was isolated using TRIzol (Invitrogen) according to
the manufacturer’s protocol. RNA was quantified using
Nanodrop spectrophotometer, and 200 ng of RNA was
reverse transcribed using 1× Moloney Murine Leukemia
Virus (MMLV) buffer (Promega), 60 U MMLV reverse
transcriptase, 0.5 M oligo d(T)15 (Promega) and 0.4
mM dNTPs (Bioline) per reaction. Quantitative reverse
transcriptase–polymerase chain reaction (qPCR) was per-
formed in triplicate for genes of interest using Platinum®
SYBR® green qPCR SuperMix-UDG with ROX (Invit-
rogen) in 384-well clear optical reaction plates using the
QuantStudio 7 Flex real-time PCR system (Applied Biosys-
tems) according to the manufacturer’s protocol. Data were
normalized against the house keeping gene hypoxanthine
phosphoribosyltransferase 1 (hprt1). Primers sequences are
described in Supplementary Table S2.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed inLNCaP andLNCaP-AR-GFP cells reverse trans-
fected with either 25 nM N/S or IKBKE siRNA for 72 h,
according to the protocol described by Schmidt et al. (27).
Briefly, 100 g of DNA and 2 g of AR antibody (Santa
Cruz Biotechnology C-19), c-MYC antibody (ab55, Ab-
Cam) or GFP antibody (ab290, AbCam) and equal quanti-
ties of non-specific isotype control antibodies (DAKO)were
used. Using primers specific toAREIII andAREII PSA en-
hancer element, AREI PSA promoter region and c-MYC
binding site within the AR promoter (Supplementary Table
S3) purified DNA fragments were analysed by qPCR. Data
were calculated as % input and presented as the average fold
difference of % input between different experimental arms
for three independent experiments.
Cell growth analysis
Cell growth was assessed using the IncuCyte ZOOM live
cell imager (Essen) according to the manufacturer’s rec-
ommendations. In each case, cells were treated and grown
in their respective normal growth media, unless other-
wise stated. For knockdown experiments, cells were reverse
transfected with 25 nM siRNA using RNAiMax according
to the manufacturer’s protocol. For compound assays, cells
were seeded and allowed to adhere for 24 h, prior to the ad-
dition of compound. Images were taken every 6 h for at least
three doubling times. The IncuCyte ZOOM2015A software
package was trained to identify cells from each cell line and
measure the % confluence of each well. Cell confluence was
normalized for each well at the 0 time point and the rela-
tive change in cell confluence was calculated for each time
point thereafter. Data were presented as the mean relative
cell confluence at each time point from at least three inde-
pendent experiments.
Cell cycle analysis
LNCaP cells were reverse transfected with 25 nM siRNA
using RNAiMax according to the manufacturer’s protocol
and grown for 96 h. Cells were collected in 100 l citrate
buffer (0.25 M sucrose, 40 mM sodium citrate, pH 7.6).
DNA staining and lysis buffer (20 g/ml propidium iodide
(Sigma), 0.5% NP-40 (Calbiochem), 250 g/ml RNaseA
(Qiagen) 0.5 mM ethylenediaminetetraacetic acid (EDTA),
in PBS) was prepared and 400 l added to the cell sus-
pension and incubated for 40 mins in the dark at 4◦C. Us-
ing FACScan together with CellQuest software (Beckton
Dickenson) 10 000 events were collected and analysed us-
ing Cyflogic software (CyFlo Ltd). The percentage of cells
in each cell cycle phase was determined and data presented
as the mean % of cells from three independent experiments
+/− SEM. Student’s t-test was used to determine statistical
significance between the experimental conditions.
Animal studies
CWR22Rv1 cells (1 × 106 per mouse) were implanted sub-
cutaneously in 0.2mlMatrigel intoCD1nudemice (Charles
Rivers, Kent, UK). Once palpable tumours were detected at
an average volume of 100 mm3, CYT387 was administered
via daily oral gavage at a dose of 100 mg/kg or vehicle con-
trol. Tumour volume was measured using callipers accord-
ing to the equation a2 × b/2, (a = smallest measurement;
b = largest measurement). Median relative tumour volume
(RTV) was calculated, where RTV1 = tumour volume on
day 1 of treatment for each mouse. Time to RTV4, defined
as the time it takes for tumours to reach four times the initial
volume, was calculated as described previously (28).Murine
body weight was also measured following daily dosing.
The in vivo experiments were approved by the local
animal welfare ethics review body (AWERB) and per-
formed according to ethical guidelines set out by Workman
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et al. under a UK home office licence in accordance with
the Animals (Scientific Procedures) Act 1986 (29).
Explant culture of human prostate tumours
Following ethical approval, human PC tissue was obtained
with written, informed consent from patients with known
PC undergoing robotic radical prostatectomy (RRP) or
channel transurethral resection of the prostate (chTURP).
Ex vivo explant cultures were established as described
by Centenera et al. (30). Collected tumour tissue was dis-
sected into ∼1–2 mm3 pieces and placed on pre-soaked
1 cm3 gelatin sponges (Spongostan Dental) in a 24-well
plate containing 500 l RPMI-1640 HEPES modification
medium (Sigma-Aldrich) with 10% foetal calf serum and
1% L-Glutamine supplemented with 1× antibiotic anti-
mycotic solution (Sigma-Aldrich), 0.01 mg/ml hydrocor-
tisone (Sigma-Aldrich), 0.01 mg/ml bovine insulin solu-
tion (Sigma-Aldrich) and synthetic androgen 1 nM R1881.
Treated explants were cultured in ex vivo medium contain-
ing CYT387 (10 M). Control explants were treated with a
matched volume of DMSO. Explants were cultured at 37◦C
with 5% CO2 for 48 or 72 h before being formalin-fixed and
paraffin embedded. Patient information detailed in Supple-
mentary Table S4.
Immunohistochemistry
Four m-thick sections of formalin-fixed paraffin-
embedded (FFPE) explant tissue were stained for the
proliferative marker Ki67. Automated immunohistochem-
istry (IHC) was carried out on a Discovery XT staining
module (Roche). Antigen was retrieved by incubating
slides in Cell Conditioning Solution (Roche). Endogenous
peroxidase activity was reduced by incubating slides in
Inhibitor CM (Roche). Slides were incubated in Ki67
primary antibody (Novocastra; 1:100) or Anit-AR primary
antibody (clone G122-434, BD) for 1 h at 37◦C followed
by HRP-conjugated Discovery OmniMaP HRP secondary
antibody (Roche) for 30 min. A ChromoMap DAB kit
(Roche) was used for detection. Slides were counterstained
in hematoxylin and mounted in DPX. Stained slides were
imaged using an Aperio CS2 Digital Pathology scanner
(Leica). Regions of interest (i.e. epithelial cells) were manu-
ally annotated and the percentage of Ki67 positive cells was
determined using Aperio Image Analysis software (Leica)
in a minimum of four representative 40× magnification
regions containing a total of at least 1000 nuclei. Positive
control tissue for Ki67 is shown in Supplementary Figure
S8 alongside no primary control staining. Serial sections
were also stained for p63 (basal cell marker identifying
benign regions) and AMACR (cancer cell marker) to define
regions of cancer (Supplementary Figure S9).
Statistical analysis
The numbers of independent experimental repeats are
detailed within figure legends. Where data is expressed
as mean ± SEM of three or more independent experi-
ments, statistical analysis was performed to indicate signif-
icance. Specifically, Student’s t-test was used for data sets
containing two experimental arms and one-way ANOVA
with Greenhouse-Geisser correction and Dunnett’s multi-
ple comparison test was performed where there were three
or more experimental arms to the experiment. Two-way
ANOVA with Dunnett’s multiple comparison test was per-
formed on data with two variables. Tests were undertaken
in GraphPad Prism 6 software.
Study approval
The NHS Health Research Authority NRES Committee
North East, Newcastle and North Tyneside, has provided
approval for human tissue studies in the laboratory of Dr.
McCracken (REC reference: 15/NE/0400).
The in vivo experiments were approved by the local an-
imal welfare ethics review body (AWERB) and the Home
Office in accordance with the Animals (Scientific Proce-
dures) Act 1989.
RESULTS
IKBKE is required for AR transcriptional activity
To identify protein kinases required for AR mediated tran-
scriptional regulation, a primary unbiased siRNA library
screen (Dharmacon) was performed, in which each kinase
in the human genome was individually depleted in andro-
gen sensitive LNCaP-7B7 (24) cells in the presence of the
synthetic AR agonist, R1881. This LNCaP derivative cell
line was selected to enable high-throughput assessment of
AR transcriptional activity by measuring AR regulated lu-
ciferase activity as a surrogate. Candidate validation was
performed by a secondary screen, consisting of independent
pools of MISSION (Sigma) siRNAs, identifying a role for
the threonine serine kinase, IKBKE in AR transcriptional
activation (Supplementary Figure S1A). Validation using
a deconvoluted siRNA pool in parental LNCaP cells con-
firmed that IKBKE knockdown significantly reduced ex-
pression of the AR target genes, prostate specific antigen
(PSA) and transmembrane serine protease 2 (TMPRSS2)
in the presence or absence of exogenous androgen (R1881)
stimulation (Figure 1A, B). Additionally, parallel screen-
ing performed in an androgen–independent version of the
LNCaP cell line, LNCaP-AI AREIII-LUC, also confirmed
IKBKE as a regulator of AR transcriptional activity both
in the presence and absence of androgenic stimulation (Sup-
plementary Figure S1B, C). Consistent with this result, in
the parental LNCaP-AI cells IKBKE knockdown dimin-
ished PSA and TMPRSS2 levels (Figure 1C). Due to the
role of constitutively active AR splice variants (AR-Vs) in
the development of advanced PC we predicted that IKBKE
would influence AR-V regulated gene expression. Variant
expressing CWR22Rv1 cells were examined for TMPRSS2
and CCNA2 expression subsequent to IKBKE knockdown
in steroid depleted media where only AR-Vs, which lack
the ligand binding domain, will be active. Indeed, consti-
tutively active AR-V mediated transcriptional activation of
TMPRSS2 and CCNA2 was impeded by IKBKE knock-
down (Figure 1D). Taken together these results validate a
critical role for IKBKE signalling in maintaining AR activ-
ity throughout PC progression.
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Figure 1. IKBKE is required for AR signalling. (A) LNCaP cells were reverse transfected in steroid depleted media (SDM) with either N/S or three
individual siRNAs against IKBKE. After 72 h, cells were stimulated with R1881 (1 nM) then PSA, TMPRSS2 and IKBKEmRNA expression determined
at 24 h by qPCR (n = 3). (B) LNCaP cells were reverse transfected in full media with either N/S or three individual siRNAs against IKBKE. After 72 h,
PSA, TMPRSS2 and IKBKE mRNA expression determined by qPCR (n = 3). (C) LNCaP-AI were transfected in SDM with either N/S or three pooled
siRNAs against IKBKE. After 72 h, cells were stimulated with R1881 (1 nM) then PSA, TMPRSS2 and IKBKEmRNA expression determined at 24 h by
qPCR (n = 3). (D) CWR22Rv1 cells were transfected with either N/S or pooled siRNAs against IKBKE in SDM, 72 h later cells were lysed and assessed
for TMPRSS2, CCNA2 and IKBKE expression by qPCR (n = 3). qPCR data is expressed as mean fold change of three experimental repeats ± SEM.
One-way ANOVA paired Dunnetts multiple comparison test * P < 0.05, ** P < 0.01; *** P < 0.001 **** P < 0.0001.
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IKBKE regulates AR mRNA levels
As IKBKE modulates the expression of genes which can
be driven by both full length AR and AR-Vs we ques-
tioned whether IKBKE could alter AR levels as a mech-
anism underlying these observations. Firstly, we examined
the effects of IKBKE knockdown using both a pool of three
siRNAs and individual siRNAs in LNCaP cells growing in
serum containing media. After 72 h, western blotting con-
firmed IKBKE knockdown, and PSA expression was inhib-
ited but further demonstrated that total AR protein levels
were found to be robustly reduced (Figure 2A). LNCaP-AI
cells, amodel of androgen independent PC, grown in steroid
depleted media similarly exhibited reduced AR protein lev-
els upon IKBKE knockdown (Figure 2B, Supplementary
Figure S2A). In addition, to ensure these effects were not
cell line dependent, the effect of IKBKE knockdown was
extended to the androgen dependent LAPC4 cell line (Sup-
plementary Figure S2B) and AR-V expressing models of
castrate resistant prostate cancer (CRPC), CWR22Rv1 and
VCaP cell lines, where consistently it was observed that
both under androgen deprived (SDM) and androgen replete
(FM) conditions, both AR and AR-V expression was re-
duced (Figure 2C, D; Supplementary Figure S2C). Com-
bined, this data suggests that IKBKE plays a robust role
in the regulation of AR levels within multiple pre-clinical
cell line models, representative of androgen sensitive and
CRPC.
Two alternative mechanisms may explain how IK-
BKE could modulate AR protein levels; either through
proteasomal-mediated regulation of AR protein turnover
or by regulation of AR mRNA. To determine whether AR
down regulation is a consequence of enhanced AR turnover
in response to IKBKE knockdown we monitored AR ex-
pression upon IKBKE knockdown in the presence of the
proteasomal inhibitor, MG132. Interestingly, we observed
that AR expression could not be restored by the addition of
MG132 suggesting that IKBKE does not play a role in AR
destruction by the proteasome (Figure 2E). Secondly, the
role of IKBKE in the regulation of AR mRNA was tested
by qPCR following IKBKE knockdown in LNCaP and
LNCaP-AI cells. This revealed that IKBKE knockdown
(Figure 1A, B) caused a significant reduction in ARmRNA
levels in LNCaP (Figure 2F) and LNCaP-AI (Figure 2G)
cells. Furthermore, both full length and AR-V7 mRNA
transcripts were significantly reduced in CWR22Rv1 cells
upon IKBKE knockdown (Figures 1D and 2H). As we
have observed a robust reduction in both AR mRNA and
protein levels in response to IKBKE knockdown we asked
whether this consequently led to reduced AR association
with androgen responsive elements in promoter-enhancer
regions of AR regulated genes, causing reduced target gene
expression. ChIP in LNCaP cells depleted of IKBKE re-
vealed a significant ∼75% reduction in AR binding to
the PSA enhancer (P < 0.001) (Figure 2I). Together, this
data suggests that IKBKE plays a role in the regulation
of AR mRNA which reduces the levels of AR protein
available to positively associate with AR regulated genes
as its primary mechanism of action on the AR signalling
pathway.
IKBKE can affect AR transcriptional activity independent of
its effects on AR mRNA
Due to the severity of the effect of IKBKE knockdown
on AR protein levels as a consequence of inhibited AR
mRNA expression it is challenging to determine whether
IKBKE can also modulate AR transcriptional activity in-
dependently of the effects on AR levels. To address this
question we utilized a LNCaP cell line which has been engi-
neered to constitutively express AR-GFP from a constitu-
tive CMV promoter (Supplementary Materials and Meth-
ods; Supplementary Figure S3A, B). Firstly, knockdown of
IKBKE was performed and PSA expression investigated
by western blotting after 72 h. This revealed that IKBKE
can also modulate the transcriptional activity of the AR in-
dependent of its effect on endogenous AR mRNA expres-
sion with a robust reduction in PSA protein levels being
observed with IKBKE knockdown even though AR-GFP
expression was unaffected (Figure 3A; Supplementary Fig-
ure S3C). Finally, to confirm that AR-GFP can bind to the
PSA enhancer we performed ChIP assays under these same
conditions. Upon IKBKE knockdown we observed a sig-
nificant 61.3% reduction in AR association (P < 0.05) with
the PSA promoter-enhancer region comparable with con-
trol IgG background levels (Figure 3B; Supplementary Fig-
ure S3D). Furthermore, ChIP using an anti-GFP antibody
confirmed that AR chromatin association is affected inde-
pendent of transcriptional down regulation of endogenous
AR levels, with a significant 65.6% reduction similar to IgG
control background levels (Figure 3B; Supplementary Fig-
ure S3E).
Collectively, these data indicate that IKBKE knockdown
mediates its effects on AR signalling mainly by suppressing
AR mRNA expression but also by inhibiting protein activ-
ity suggesting that IKBKE is amajor node ofAR regulation
in PC cells.
Pharmacological antagonism of IKBKE suppresses AR ex-
pression and transcriptional activity
To determine whether IKBKE is clinically relevant in PC
we investigated publically available data in cBioportal in the
first instance. Indeed, upon investigation of all prostate data
sets, it appears that IKBKE is amplified in CRPC (27.14%;
19/70 cases) compared to prostate adenocarcinoma (1.74%;
82/4712 cases) and normal prostate (0%; 0/313 cases) (Sup-
plementary Figure S4A). Furthermore, genetic alterations
in IKBKE within these data sets is significantly associated
with poorer survival (Supplementary Figure S4B) suggest-
ing that therapeutic targeting of IKBKE may provide pa-
tient benefit.
IKBKE inhibitors have been developed and used in clin-
ical trials to treat patients with Type 2 diabetes (22). There-
fore, if the kinase activity is responsible for effects on AR
levels these available inhibitors may expedite new PC ther-
apies. To discriminate between the kinase-dependent and -
independent functions of IKBKE inAR signalling, LNCaP
cells were treated with the small molecule IKBKEkinase in-
hibitor, CAY10576 (31). Consistent with the observations
following IKBKE depletion, pharmacologically antagoniz-
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Figure 2. IKBKE regulates ARmRNAexpression. (A) LNCaP cells were transfected in serum containingmedia (FM)withN/S or three individual/pooled
siRNAs against IKBKE. After 72 h, (A) PSA, AR and IKBKE expression was determined by immunoblotting. (B) LNCaP-AI cells were transfected in
steroid depleted media (SDM) with N/S or three pooled IKBKE siRNAs. After 72 h, PSA and AR expression was assessed by immunoblotting. (C)
CWR22Rv1 and (D) VCaP cells were transfected with N/S or pooled IKBKE siRNAs and grown in either FM or SDM as indicated. After 72 h, PSA and
AR expression were determined by immunoblotting. (E) LNCaP cells were transfected with N/S or pooled IKBKE siRNAs. After 40 h, the proteasomal
inhibitor MG132 (20 M) was applied for 16 h. PSA and AR expression was determined by immunoblotting. (F) LNCaP cells were transfected in SDM
with N/S or three individual IKBKE siRNAs. After 72 h, R1881 was applied for 24 h then AR mRNA quantified by qPCR (n = 3). One-way ANOVA
paired Dunnetts multiple comparison test. (G) LNCaP-AI cells were transfected in SDM with N/S or three individual IKBKE siRNAs. After 72 h,
cells were stimulated with R1881 (1 nM) then AR mRNA expression determined at 24 h by qPCR (n = 3). One-way ANOVA paired Dunnetts multiple
comparison test (H) CWR22Rv1 cells were transfected with N/S or IKBKE siRNA pool in SDM. After 72 h full length AR (AR-FL) and AR-V7 gene
expression was analysed by qPCR (n = 3). Student’s t-test. (I) LNCaP cells were transfected with N/S or pooled IKBKE siRNAs. After 72 h, chromatin
immunoprecipitation for AR was performed and recruitment to the PSA enhancer assessed by qPCR (n= 3). One-way ANOVA paired Dunnetts multiple
comparison test * P < 0.05, ** P < 0.01; *** P < 0.001. P: pooled siRNA.
ing IKBKE either prior to R1881 stimulation in steroid de-
pleted media led to a robust, dose-dependent reduction in
PSA andARprotein expression (Figure 4A), as well asPSA
and AR mRNA levels (Figure 4B) at effective concentra-
tions previously described (20). Similarly, a significant dose
dependent decrease inARmRNA levels was seenwhen cells
were treated in serum containing media (Figure 4C). To
confirm these findings, additional IKBKE inhibitors were
evaluated. Firstly, BX795, which can also inhibit TBK1,
PDK1, p38 and JNK resulted in a significant reduction in
PSA mRNA and protein levels and also reduced AR levels
consistent with the CAY10576 data (Supplementary Figure
S5A, B). A second generation version of BX795, termed
MRT67307, which does not inhibit JNK or p38, demon-
strated consistent inhibitory effects on PSA levels (Supple-
mentary Figure S5C, D). Thirdly, CYT387, which was de-
veloped as a JAK inhibitor but can also target IKBKE and
TBK1, resulted in a significant dose dependent reduction
in PSA and AR mRNA and protein levels in LNCaP cells
(Figure 4D, E). Furthermore, total IKBKE protein levels
appear to be unaffected in response to IKBKE inhibition
with the exception of CYT387, consistent with other pub-
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Figure 3. IKBKE inhibits AR transcriptional activity. LNCaP-AR-GFP cells were reverse transfected with individual IKBKE targeting siRNAs or a pool
of siRNA 1 and 2 for 72 h. (A) Lysates were then collected and western blotting performed for PSA, endogenous AR and GFP tagged AR. Alpha tubulin
was used as a loading control. Blots are representative of 2 experimental repeats. (B) Chromatin immunoprecipitation using either anti-AR antibody, anti-
GFP antibody or IgG control was performed and recruitment to the PSA enhancer was assessed by qPCR (n = 3). Data is expressed as mean fold change
relative to N/S control ± SEM. Unpaired one-way ANOVA * P < 0.05.
Figure 4. IKBKE catalytic activity is required for AR protein expression and transcriptional activation. After 72 h steroid depletion, LNCaP cells were
pre-treated with either vehicle (DMSO) or increasing concentrations of IKBKE antagonist, CAY10576, for 8 h followed by treatment with either vehicle
(DMSO) or 1 nMR1881 for a further 24 h. (A) Lysates were assessed for PSA, AR and IKBKE protein expression by immunoblotting or resultant cDNA
was assessed for (B) PSA mRNA and AR mRNA expression by qPCR (n = 2). (C) LNCaP cells grown in full media were treated with either vehicle or
increasing concentrations of CAY10576 for 16 h. ARmRNA levels were determined by qPCR (n = 2). (D) After 72 h steroid depletion, LNCaP cells were
pre-treated with either vehicle or increasing concentrations of CYT387 for 8 h followed by treatment with either vehicle or 1 nM R1881 for a further 24
h. PSA and AR mRNA expression determined by qPCR (n = 3) and (E) PSA, AR and IKBKE protein expression was determined by immunoblotting.
Data is expressed as mean fold change of independent experiments ± SEM. Western blots are representative of at least 2 experimental repeats. -tubulin
was used as a loading control. One-way ANOVA, Dunnett’s multiple comparisons test * P < 0.05, ** P < 0.01, *** P < 0.001.
lished data. Taken together, these data support a role for
IKBKE catalytic activity in AR mediated transcription by
facilitating de novo AR synthesis.
IKBKE regulates AR mRNA expression via the Hippo path-
way
As IKBKE is a cytosolic protein which can influence AR
mRNA production and AR activity we hypothesize that
other proteins are involved as intermediaries between IK-
BKE and AR. Firstly, we suspected NF-B signalling may
be implicated as IKBKEhas previously been shown to stim-
ulate NF-B activation via phosphorylation at S468 to en-
hance RelA nuclear localization (32) as well as regulate
AR mRNA expression (33). However, we did not observe
any p65 in the nucleus of LNCaP cells under non-silencing
(N/S) conditions (Supplementary Figure S5E) suggesting
that NF-B is not activated and therefore unlikely to be
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playing a role in the regulation of AR mRNA in these ex-
periments.
IKBKE is also a regulator of theHippo pathwaywhereby
it both directly and indirectly, via large tumour suppres-
sor serine/threonine kinases 1/2 (LATS1/2), controls the
stability and nuclear translocation of the transcriptional
co-activator Yes-associated protein (YAP) (13). The Hippo
pathway has been found to be frequently deregulated in can-
cer where it plays a critical role in the regulation of cell
fate and tissue growth. Interestingly, YAP has recently been
identified as a direct co-activator of the AR (34) and may
indirectly regulate AR mRNA via the transcriptional reg-
ulation of its downstream target gene, c-MYC which has
been shown to modulate AR mRNA production (34,35).
Therefore, we hypothesized that YAP and c-MYC are key
modulators of IKBKE mediated effects on AR signalling.
To test this theory, the effects of both IKBKE depletion and
pharmacological antagonism on YAP and c-MYC were in-
vestigated.
SiRNA-mediated depletion of IKBKE in LNCaP cells
grown in serum-containing media resulted in a robust re-
duction in YAP and c-MYC protein expression, alongside
a reduction in AR protein expression and AR target genes,
PSA and TMPRSS2 (Figure 5A). However YAP mRNA
levels increased 5-fold (±SEM 1.64) and 4 fold (±SEM
0.96) with two independent siRNA sequences, whilst c-
MYC mRNA was significantly reduced by >50% in re-
sponse to significant IKBKE knockdown (Figure 5B) sug-
gesting that YAP is down-regulated post-translationally by
IKBKE consistent with other reports in the literature (36).
Moreover, inhibition of IKBKEwith CAY10576 led to a re-
duction in bothYAP and c-MYCprotein levels (Figure 5C).
Interestingly, we demonstrated that depletion of IKBKE led
to a dramatic increase in LATS2 expression (Figure 5A).
As LATS2 is the kinase responsible for inactivating YAP
by promoting nuclear exclusion and degradation this fur-
ther strengthens the hypothesis that YAP post-translational
regulation is involved in IKBKE mediated effects. Indeed,
upon proteasomal inhibition with MG132, the levels of
YAP protein following IKBKE knockdown were rescued
(Figure 5D).
Upon investigation into the cellular localization of YAP
in LNCaP cells in response to IKBKE knockdown or phar-
macological inhibition, a decrease in nuclear YAP was ob-
served alongside a robust reduction in nuclear c-MYC (Fig-
ure 5E, F). As previously mentioned, c-MYC can regu-
late and promote AR de novo mRNA synthesis by bind-
ing directly to the AR gene itself (35), therefore to test
whether the reduction in nuclear c-MYC levels results in a
decrease in c-MYC binding to the AR gene, we performed
IKBKE knockdown followed by ChIP. As expected, upon
IKBKE knockdown in LNCaP cells the presence of c-MYC
at the AR gene was significantly decreased by 60% (Fig-
ure 5G). Taken together, these findings suggest that via the
regulation of Hippo signalling, in particular the stability
and cellular compartmentalization of the transcriptional
co-activator YAP and therefore de novo synthesis of its tar-
get gene c-MYC, IKBKE influences ARmRNA expression
to significantly antagonize ARmediated transcriptional ac-
tivity.
Expression of constitutively active Yap rescues AR mRNA
expression
To confirm that Yap and c-MYC are mediating AR regu-
lation in response to IKBKE knockdown we generated an
LNCaP cell line that overexpresses a constitutively active
Yap (Supplementary Figures S10–S11). As this version of
Yap, which is mutated at Serine 127, cannot be phospho-
rylated it remains in the nucleus where it can activate gene
transcription. IKBKE was knocked down in these cells and
their empty vector control cell line andARexpression deter-
mined by qPCR after 72 hours. In order to compare results
between these two cell lines we ensured that the level of IK-
BKE knockdown was as similar as possible and looked at
fold changes in AR mRNA levels. We observed that upon
IKBKE knockdown, expression of IKBKE in LNCaP-EV
was similar to that observed in the parental cell line shown
in Figure 2, particularly for siRNA IKBKE#2.When com-
pared to the LNCaP-Yap S127A cell line we see a significant
rescue in AR mRNA expression to around a 40% reduc-
tion with both siRNA sequences compared to 60–90% re-
duction in the LNCaP-EV cell line when a 60% knockdown
is achieved (Figure 6A).
In addition, to further confirm our proposed mechanism
of IKBKE action we investigated the effects of c-MYC
knockdown on AR mRNA levels. In support of our res-
cue experiment data we found that upon knockdown of
c-MYC, a reduction in AR mRNA and protein levels in
LNCaP cells (Figure 6B–D) as well as a significant reduc-
tion in LNCaP proliferation is observed (Figure 6E). Taken
together these two lines of evidence support our proposed
mechanism that IKBKE functions via Yap and c-MYC to
impact AR mRNA expression.
IKBKE is required for PCa cell growth and progression.
We next assessed the role of IKBKE in regulating the sur-
vival and proliferation of PC cell lines. To examine the phe-
notypic effect of IKBKE depletion on cellular growth, the
proliferative potential of LNCaP cells was assessed follow-
ing transfection with either N/S control or individual IK-
BKE siRNAs, using live cell imaging. In the IKBKE de-
pleted cells, proliferation began to be impaired at around
54 h post transfection and was significantly reduced by 120
h (P < 0.05), confirming that IKBKE is required for nor-
mal PC cell growth (Figure 7A). As IKBKE knockdown
results in AR inhibition from ∼48 h (data not shown) we
speculate that this reduction could be a consequence of re-
duced AR levels. Interestingly, IKBKE knockdown in AR
negative PC3 cells also reduced proliferation (Supplemen-
tary Figure S6A) suggesting that IKBKE can also influence
proliferation independent of AR. However, it does appear
that they are less sensitive to IKBKEknockdownwhen pro-
liferation rates are compared. This is particularly apparent
for siRNA #2. Additionally, cell cycle distribution evalu-
ated using flow cytometry demonstrated a significant 19%
increase of G1 phase cells alongside a significant 63% de-
crease of cells in S phase and a 53% decrease inG2/Mphase
in the IKBKE depleted cells, suggesting that IKBKE deple-
tion results in a G1 cell cycle arrest (Figure 7B). This profile
is similar to cell cycle distribution upon AR knockdown in
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Figure 5. IKBKE influences AR mRNA expression via the Hippo pathway. LNCaP cells were reverse transfected in full media (FM) with either N/S
or three pooled siRNAs against IKBKE. After 72 h, protein expression was assessed by (A) immunoblotting and (B) YAP, c-MYC and IKBKE mRNA
expression determined by qPCR (n= 3). (C) After 72 h steroid depletion, LNCaP cells were pre-treated with vehicle (DMSO) or increasing concentrations
of IKBKE antagonist, CAY10576, for 8 h followed by treatment with vehicle or 1 nM R1881 for a further 24 h. YAP and c-MYC protein levels were
assessed by immunoblotting. (D) LNCaP cells were reverse transfected in FM with either N/S or pooled siRNAs against IKBKE. After 72 h, MG132
(20 M) was applied and incubated for a further 16 h. YAP levels were determined by immunoblotting. (E) LNCaP cells were reverse transfected in
FM with either N/S or pooled siRNAs against IKBKE. After 72 h, nuclear-cytoplasmic fractionation was performed with YAP and c-MYC localization
determined by immunoblotting. PARP was used as a nuclear loading control and -tubulin as a cytoplasmic loading control. Densitometry was performed
on YAP expression and normalized to loading controls using ImageJ software. Data is expressed as a % of total cellular YAP. (F) LNCaP cells were treated
with either vehicle or CAY10576 (5 M) or CYT387 (5 M) for 16 h prior to nuclear-cytoplasmic fractionation. Nuclear YAP and c-MYC levels were
determined by immunoblotting. (G) LNCaP cells were reverse transfected in FM with either N/S or pooled siRNAs against IKBKE and grown for 48 h
prior to ChIP analysis using antibodies specific to c-MYC and isotype controls (IgG). Recruitment to the c-MYC binding site within the AR gene was
assessed by qPCR. Data are an average of 3 independent experiments ± SEM. One-way ANOVA paired Dunnetts multiple comparison test * P < 0.05,
** P < 0.01.
the LNCaP cells line as AR has been described as a ‘master
regulator’ of the transition betweenG1 and S phase (37) fur-
ther implicating links between IKBKE and AR. Moreover,
no increase in the proportion of cells in sub-G1was evident,
suggesting that IKBKE depletion is cytostatic rather than
cytotoxic. In agreement with IKBKE depletion, pharma-
cological antagonism of IKBKE in multiple PC cell lines,
resulted in a significant and dose dependent decrease in cel-
lular growth, as assessed by live cell imaging (Figure 7C) or
alternatively sulforhodamine B growth assays (Supplemen-
tary Figure S6B–D). Furthermore, ARpositive cell lines ap-
pear more sensitive to IKBKE inhibition upon comparison
of GI50 values (Supplementary Figure S6E–G) and ‘nor-
mal’ prostate cancer cells appear to be less sensitive (Sup-
plementary Figure S6H).
As high IKBKE expression was previously reported to
be associated with the development of bone metastases in
PC patients (38) we next sought to determine the migratory
ability of LNCaP cells following IKBKE suppression. IK-
BKE knockdown was carried out in serum containing me-
dia for 72 h prior to equal cell numbers being resuspended
in serum-free media and transferred into Boyden chambers
inserted into serum containing media as a chemoattractant.
After 16 h cells were fixed, stained and counted to reveal a
significant 91.7% reduction inmigration. (Figure 7D). Simi-
larly, upon IKBKE inhibition for 24 h prior to seeding into
migration chambers using the same protocol a significant
82.4% reduction in migration was observed (Figure 7E).
Furthermore, in both LNCaP and LNCaP-AI cells, IK-
BKE knockdown resulted in a significant 20-fold decrease
in colony forming ability compared with N/S controls (Fig-
ure 7F and Supplementary Figure S6I, J). Additionally, IK-
BKEdepletion prior to re-seeding significantly retarded cel-
lular adhesion, a phenomenon which may prove therapeuti-
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Figure 6. IKBKE effects on AR expression are phenocopied by c-MYC knockdown and partially rescued by overexpression of constitutively active Yap.
(A) LNCaP-EV and LNCaP-Yap-S127A were reverse transfected with two individual siRNA sequences targeting IKBKE. RNA was collected after 72 h
and assessed for expression of AR and IKBKE by qPCR (n = 3). (B) LNCaP cells were reverse transfected with either N/S or two independent siRNA
sequences targeting c-MYC. After 72 hours, RNA was collected and ARmRNA and (C) c-MYC expression levels determined by QPCR (n= 3). One-way
ANOVA, Dunnett’s multiple comparisons test * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. (D) Concurrently, protein lysates were also
collected and tested for AR and c-MYC expression by western blotting. (E) LNCaP cells were reverse transfected in full media with either N/S or two
independent siRNA sequences targeting c-MYC and cell confluency assessed using the IncuCyte Zoom Live Cell Imager every 6 h for 96 h (n = 3). 2way
ANOVA, Dunnett’s multiple comparisons test **** P < 0.0001.
cally beneficial in preventing the engraftment and coloniza-
tion of metastatic cells (Supplementary Figure S6K). Taken
together these results suggest that diminishing IKBKE sig-
nalling in PC cells may prove therapeutically beneficial for
patients by suppressing AR signalling to prevent cancer cell
growth and metastases.
IKBKE is required for endocrine therapy-resistant cell growth
Identifying novel therapeutic targets within the AR sig-
nalling cascade is essential to overcome endocrine therapy-
resistant disease. As high IKBKE expression is correlated
with castration resistance (38) we therefore next sought to
investigate the effect of IKBKE depletion and pharma-
cological antagonism on endocrine therapy-resistant PC
cell growth. The LNCaP-enzalutamide resistant cell line,
LNCaP-EnzR and the CWR22Rv1 cell line both represent
models of endocrine therapy-resistant disease, in which cells
continue to grow and respond to androgenic stimuli in the
presence of the anti-androgen enzalutamide. Proliferation
tracking upon IKBKE knockdown revealed a significant
44% reduction in proliferation at 120 h in LNCaP-EnzR
cells (P < 0.05) (Figure 8A) which was consistent with cell
counts (Supplementary Figure S7A). Furthermore, analy-
sis of AR, TMPRSS2 and FKBP5 mRNA and protein ex-
pression showed that AR signalling was significantly inhib-
ited (Figure 8B,C). Colony forming ability was also reduced
upon IKBKE knockdown in this cell line (Figure 8D). A
similar repression of proliferation was apparent with all IK-
BKE small molecule inhibitors in both LNCaP-EnzR (Fig-
ure 8E) and CWR22Rv1 (Figure 8F) cells. Moreover, IK-
BKE knockdown was found to still inhibit the growth of
CWR22Rv1 cells in the presence of Enzalutamide (Figure
8G) indicating that IKBKE can also influence AR vari-
ant facilitated cell growth. Furthermore, both full length
and variant AR proteins showed decreased expression in
VCaP cells upon IKBKE knockdown in the presence of en-
zalutamide (Supplementary Figure S7B). The data there-
fore indicates that IKBKE continues to regulate AR sig-
nalling in cells which have developed endocrine therapy re-
sistance and therefore pharmacological antagonism of IK-
BKE could potentially be used to treat both primary and
endocrine therapy-resistant disease.
IKBKE is therapeutically targetable in PC in vivo
The efficacy of IKBKE pharmacological antagonism in
vivo was tested using the Phase III, dual IKBKE/JAK2
antagonist, CYT387, on CWR22Rv1 tumour xenograft
growth. This inhibitor was favoured over CAY10576 as
it has superior chemical properties for in vivo studies. As
this inhibitor also has JAK2 activity we first compared the
growth of CWR22Rv1 cells in vitro, in the presence of ei-
ther CYT387 or a specific JAK2 inhibitor, Ruxolitinib. This
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Figure 7. IKBKE is required for PC cell growth and survival. (A) LNCaP cells were reverse transfected in full media with either N/S or pooled siRNAs
against IKBKE and cell confluency assessed using the IncuCyte Zoom Live Cell Imager every 6 h for 96 h (n = 4). Two-way ANOVA, Dunnett’s multiple
comparisons test **** P < 0.0001. (B) LNCaP cells were treated as in (A) prior to harvesting at 96 h for cell cycle analysis by propidium iodide flow
cytometry. Data shows the % of cells in each phase of the cell cycle (n = 3). Pearson’s Chi-squared test revealed a significant difference between N/S
and IKBKE knockdown treatments (P < 10−15); two-way ANOVA (variables: cell cycle phase and siRNA treatment) with multiple comparisons reveals
significant differences between individual phases. * P < 0.05, ** P < 0.01, **** P < 0.0001. (C) LNCaP cells were treated with either vehicle or increasing
concentrations of the IKBKE inhibitor CAY10576 in full media and cell confluency assessed as described as in A (n = 3). Two-way ANOVA, Dunnett’s
multiple comparisons test, ns – not significant, ** P < 0.01, *** P < 0.001, **** P < 0.0001. (D) LNCaP cells were reverse transfected in full media with
either N/S or pooled siRNAs against IKBKE and incubated for 72 h prior to cell counting and equal numbers being resuspended in basal media and
dispensed into Boyden chambers suspended in full media as a chemoattractant, in triplicate. (E) Similarly, LNCaP cells were incubated in the presence of
the IKBKE inhibitor CAY10576 for 24 hours prior to counting, resuspension in basal media and transfer to Boyden chambers. Chambers were incubated
for 16 h prior to cell fixation, staining and counting. Chambers were set up in triplicate per condition. Data shown is expressed as mean cell number ± SD
for 1 representative experiment of two independent experiments. (F) LNCaP cells were transfected in full media with either N/S or three pooled siRNAs
against IKBKE. After 72 h, cells were re-seeded at a density of 2000 cells per well and cultured for 2 weeks. Colony forming efficiency was assessed by
fixing and staining colonies with crystal violet (n = 3). Student’s t-test **** P < 0.0001.
showed that JAK2 inhibition does not inhibit the growth of
CWR22Rv1 cells (Supplementary Figure S7C) hence any
effect of CYT387 in CWR22Rv1 cells can be attributed to
inhibition of IKBKE and not JAK2. After tumours were es-
tablished in immunodeficient mice (average tumour volume
100 mm3), CYT387 was administered via daily oral gavage
at a dose of 100 mg/kg. Compared with a vehicle control,
CYT387 treatment at this dose effectively inhibited tumour
growth (Figure 9A) and significantly delayed tumour pro-
gression (Figure 9B), with no deleterious effects on murine
body mass (Figure 9C). We next explored the therapeutic
potential of IKBKE antagonism using CYT387 in a sys-
tem that more closely recapitulates human tumour physiol-
ogy using patient-derived prostate tissue explants. Similar
to CWR22Rv1 xenografts, CYT387 treatment impaired the
growth of explant prostate glandular tissue, as measured by
the prevalence of Ki67 positive nuclei (Figure 9D, E; Sup-
plementary Figure S8, Supplementary Table S4). Further-
more, we demonstrate that AR expression is reduced in re-
sponse to CYT387 treatment (Supplementary Figures S9A,
B). Taken together, these findings suggest that inhibition of
IKBKE signalling in PC suppressesARmediated transcrip-
tional activation and cellular growth and the utilization of
small molecule inhibitors of IKBKE may exhibit therapeu-
tic potential for the treatment of both androgen sensitive
and therapy resistant PCs.
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Figure 8. IKBKE is required for AR-target gene expression and cell growth in treatment-resistant PC cells. (A) LNCaP-EnzR cells were reverse transfected
in full media with either N/S or two independent siRNAs against IKBKE and cell confluency assessed using the IncuCyte Zoom Live Cell Imager every
6 h for 96 h (n = 3). (B) LNCaP-EnzR cells were treated as in (A) after 96 h, AR, TMPRSS2, FKBP5 and IKBKE expression was determined by
immunoblotting and (C) AR, TMPRSS2, FKBP5 and IKBKE mRNA expression determined by qPCR (n = 3). (D) LNCaP-EnzR cells were transfected
in full media with either N/S or three pooled siRNAs against IKBKE. After 72 h, cells were re-seeded at a density of 2000 cells per well and cultured for
2 weeks. Colony forming efficiency was assessed by fixing and staining colonies with crystal violet (n = 3). (E) LNCaP-EnzR cells were seeded and left to
adhere and grow for 24 h, prior to treatment with either vehicle (DMSO) or the IKBKE antagonists, CAY10576 (5 M), BX795 (5 M), MRT67307 (5
M), or CYT387 (5 M) and cell confluency assessed using the IncuCyte Zoom Live Cell Imager every 6 h for 96 h (n = 2). (F) CWR22Rv1 cells were
seeded and left to adhere and grow for 24 h, prior to treatment with either vehicle or CAY10576 (5 M), BX795 (5 M), MRT67307 (5 M), or CYT387
(5 M) and cell confluency assessed using the IncuCyte Zoom Live Cell Imager every 6 h for 96 h (n = 2). (G) CWR22Rv1 cells were reverse transfected
with either N/S or three pooled siRNAs against IKBKE, in full media supplemented with 10 M Enz and cell confluency assessed using the IncuCyte
Zoom Live Cell Imager every 6 h for 120 h (n = 3). 2way ANOVA, Dunnett’s multiple comparisons test used in A, E, F and G **** P < 0.0001. One-way
ANOVA paired Dunnetts multiple comparison test used in C and D * P < 0.05, ** P < 0.001.
DISCUSSION
The AR remains a key therapeutic target in advanced,
anti-androgen resistant disease. As an alternative means to
reduce AR activity when anti-androgens have failed, co-
regulator proteins which control the activity of the AR can
be targeted. Indeed, many of these co-regulators are dys-
regulated in advanced disease (2). Ideally, co-activators with
enzymatic activity could be targeted with small molecule in-
hibitors to indirectly diminish AR activity. As multiple ki-
nase enzymes have been shown to play a key role in reg-
ulating AR activity and several clinically approved kinase
inhibitors are available, we chose to investigate which pro-
tein kinases may provide the greatest clinical benefit to anti-
androgen resistant patients. By interrogating the entire hu-
man kinome, we identified IKBKE as a potential AR regu-
lating protein.
Here, we demonstrate that IKBKEplays a role in the pro-
duction of AR mRNA and as such results in enhanced AR
regulated gene expression. As IKBKE mediated AR regu-
lation occurs at the level of transcription, all AR mRNA
species are affected including those which result in the pro-
duction of constitutively active splice variant forms for
which there are currently no targeted therapeutics available.
The kinase activity of IKBKE appears to be important in
regulatingARmRNAproduction therefore, we hypothesize
that inhibition of IKBKE may be therapeutically beneficial
to CRPC patients who frequently retain expression of func-
tional AR and AR-Vs. Indeed, we show that knockdown
and inhibition of IKBKE can reduce proliferation, migra-
tory ability and tumour volume supporting our hypothe-
sis that IKBKE inhibition is a viable clinical strategy. Fur-
thermore, it has been reported that high cytoplasmic IK-
BKE expression associates with the development of bone
metastases and castration resistance (38) consistent with a
role in therapy resistant disease. Indeed, treatment of enza-
lutamide resistant PC cell line models with either siRNA-
mediated knockdown or pharmacological inhibition of IK-
BKE results in a robust inhibition of proliferation.
Currently, two compounds are available in the clinic
that target IKBKE, each displaying minimal side effects;
Amlexanox and CYT387. Amlexanox, an IKBKE/TBK1
inhibitor developed to treat ulcers, allergic rhinitis and
asthma, results in a G0/G1 arrest in glioblastoma cells and
induction of apoptosis (13).We also observedG0/G1 arrest
following IKBKE knockdown in PC cells but the apoptosis
rate was unaffected. Importantly, as Amlexanox has already
been administered to humans in a clinical trial for Type 2
diabetes (22), repurposing this drug in PC patients who are
resistant to AR targeting therapies could be tested quickly.
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Figure 9. IKBKE inhibition reduces tumour volume and inhibits proliferation of PC ex vivo cultures. CWR22Rv1 cells were implanted subcutaneously
in nude mice, and following the development of established xenograft tumours, vehicle (DMSO) (n = 6) or CYT387 100 mg/kg (n = 8) was administered
daily by oral gavage. (A) Relative Tumour Volume (compared to dosing day 0) ± SD following either 12 days vehicle or CYT387 treatment. (B) Time
for CWR22Rv1 xenografts to reach 4× Relative Tumour Volume (compared to dosing day 0) ±SD following daily vehicle or CYT387 treatment. (C)
Mean murine body weight over time, following daily vehicle or CYT387 treatment. (D, E) Ex vivo cultures of two human PC tumours (patient sample
A (chTURP); patient sample B (RRP)) were established and treated with either vehicle or IKBKE inhibitor CYT387 (10 M) for 48 h. Expression of
the proliferative marker Ki67 was then assessed in treated explant tissue sections by immunohistochemistry and digitally quantified. Data is expressed
as percentage of cells positively stained for Ki67. Representative images of Ki67 staining are shown. Mann–Whitney U test; two-tailed: *P < 0.05, ** P
< 0.01. Data points represent the percentage of Ki67-positive nuclei within a representative 40× magnification field, with a total of at least 1000 nuclei
analysed for each treatment. Error bars indicate the mean ± SEM. Scale bars = 200 m. (F) A third ex vivo culture was treated as in D and E but also
assessed for AR expression alongside AMACR (cancerous marker) and p63 (benign marker). AR staining was then scored in AMACR positive glands as
described above. chTURP, channel transurethral resection of the prostate; RRP, robotic radical prostatectomy.
In order to determine the mechanism by which cytoso-
lic IKBKE positively regulates AR mRNA we investigated
transcription factors that have been shown to regulate the
expression of AR and which functionally interact with IK-
BKE. Firstly, we ruled out NF-B inactivation as p65 is
cytoplasmic in LNCaP derivative cell lines. Secondly, c-
MYC was investigated as a mediator between IKBKE and
AR expression. Interestingly, we observed a decrease in c-
MYC protein levels in response to IKBKE knockdown or
pharmacological inhibition which resulted in decreased c-
MYC binding to the AR gene. We confirmed that c-MYC
down-regulation was at the transcriptional level and not
due to increased c-MYC turnover. This contrasts with ob-
servations in pancreatic ductal adenocarcinoma cell lines
where IKBKE mediated phosphorylation of Akt and sub-
sequent inhibition of GSK3 regulates the nuclear reten-
tion and stabilization of c-MYC without impacting on c-
MYC mRNA (14). However, these differences could possi-
bly be explained by the presence of a constitutively active
Akt and low GSK3 activity in LNCaP cells (39). In addi-
tion, during the preparation of this manuscript c-MYC was
identified as a transcriptional and functional regulator of
the splicing factor Sam68 (40) which has been shown to be
a key factor in the production of AR splice variants (41,42)
further supporting a role for IKBKE, as an upstream regu-
lator of c-MYC, in driving CRPCs.
Numerous studies describe c-MYC as transcriptionally
regulated by YAP, a component of the Hippo pathway
(13,43,44). As YAP has been widely studied in the con-
text of PC we investigated further and found that IKBKE
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Figure 10. Model of IKBKEmediated AR signalling. (A) IKBKE up-regulation in prostate cancer enhances the ubiquitination and turnover of LATS2 in
a kinase dependent manner. This is turn promotes nuclear localization of YAP and transcription of YAP regulated genes, including c-MYC. Up-regulated
levels of nuclear c-MYC result in up-regulation of c-MYC regulated genes, such as AR. This results in a large pool of AR in cells which in turn, upon ligand
mediated activation can also be co-activated by nuclear YAP. (B) Upon inhibition of IKBKE kinase activity, LATS2-Ub is impaired allowing the protein
to accumulate and phosphorylate YAP. Phosphorylated YAP is held in the cytoplasm and subsequently targeted for proteasomal degradation. This results
in c-MYC downregulation which in turn results in AR down-regulation, including constitutively active AR splice variants, and therefore AR regulated
gene expression. Ub, ubiquitin; P, phosphate.
knockdown or inhibition reduced the total and nuclear
levels of YAP supporting a role for YAP in this mecha-
nism. Conversely, we observed that IKBKE knockdown
increased YAP mRNA expression suggesting that the ob-
served decrease in protein level is due to an increase in YAP
turnover. Indeed, enhancedYAP turnover via the ubiquitin-
mediated proteasomal pathway has been reported as a con-
sequence of IKBKE mediated phosphorylation and activa-
tion of LATS (13). Consistent with this, we observed that
IKBKE knockdown resulted in enhanced YAP proteaso-
mal degradation which was rescued by the addition of the
proteasomal inhibitor MG132. Furthermore, it is evident
that the rate of YAP turnover dominates over the increased
YAP mRNA levels which is a consequence of relieved YAP
promoter methylation normally facilitated by AR interact-
ing with EZH2 and DNMT1 (43).
Whilst IKBKE regulation of AR mRNA production ap-
pears to be the primary mechanism of control, we have evi-
dence that IKBKE affects AR transcriptional activity inde-
pendently of de novo protein synthesis. Upon knockdown
of IKBKE in LNCaP cells engineered to constitutively over
express a GFP-tagged AR driven by a CMV promoter, no
alterations in AR-GFP protein levels were observed, how-
ever PSA levels were robustly depleted. Furthermore, AR-
GFP recruitment to the PSA enhancer was significantly re-
duced.One potentialmechanismwhereby IKBKE regulates
AR protein activity may be via IKBKE-mediated AKT
phosphorylation at Thr308/ Ser473 sites. Activated pAKT
can directly phosphorylate AR to promote activation (45)
or indirectly act via GSK3 Ser9 phosphorylation that sub-
sequently causes AR activation (46). The IKBKE-targeted
LATS andYAP proteins are also reported to impact AR ac-
tivity (34,47). Furthermore, we observed that AR positive
cell lines were more sensitive to IKBKE inhibition than AR
null cell lines. Hence, multiple links exist between increased
expression of IKBKE and enhanced AR transcriptional ac-
tivity.
With links established between IKBKE gene amplifica-
tion andAR independent neuroendocrine PCs and our data
regarding IKBKE knockdown and PC3 cellular prolifera-
tion we acknowledge that there is a potential for AR in-
dependent effects. Indeed, IKBKE expression in PC3 cells
is much higher than in LNCaP cells. Interestingly, upon
knockdown of c-MYC in PC3 cells a robust inhibition of
cellular proliferation is observed which would explain why
IKBKE knockdown, which decreases c-MYC levels, has
this effect. Whilst this requires further investigation, there
is also scope to investigate the utility of IKBKE targeting
therapeutics in highly aggressive AR negative tumours.
In summary, this study demonstrates that IKBKE plays a
role in AR signalling. Small molecule inhibitors of IKBKE
kinase function diminishes AR signalling by simultaneous
downregulation of AR mRNA and transcriptional activity.
This downregulation is a result of IKBKE crosstalk with
the Hippo pathway resulting in LATS2 upregulation, which
in turn downregulates YAP by phosphorylation-mediated
nuclear exclusion and degradation, to deplete its transcrip-
tional target c-MYC which is important in the produc-
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tion of AR mRNA (Figure 10). The inhibition of this sig-
nalling pathway results in favourable phenotypic outcomes
linked to cancer therapeutics such as reduced AR regulated
gene expression, decreased migratory ability, reduced tu-
mour volume and reduced proliferative potential. As YAP
is reported to be upregulated in CRPC and to be responsi-
ble for androgen-independent growth, we propose that tar-
geting IKBKE will help to overcome YAP-mediated effects
and be of particular benefit to patients who develop resis-
tance to current AR targeting therapies.
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